Browse > Article
http://dx.doi.org/10.9718/JBER.2021.42.6.287

An Artificial Neural Network-Based Drug Proarrhythmia Assessment Using Electrophysiological Characteristics of Cardiomyocytes  

Yoo, Yedam (Dept of IT Convergence Engineering, Kumoh National Institute of Technology)
Jeong, Da Un (Dept of IT Convergence Engineering, Kumoh National Institute of Technology)
Marcellinus, Aroli (Dept of IT Convergence Engineering, Kumoh National Institute of Technology)
Lim, Ki Moo (Dept of Medical IT Convergence Engineering, Kumoh National Institute of Technology)
Publication Information
Journal of Biomedical Engineering Research / v.42, no.6, 2021 , pp. 287-294 More about this Journal
Abstract
Cardiotoxicity assessment of all drugs has been performed according to the ICH guidelines since 2005. Non-clinical evaluation S7B has focused on the hERG assay, which has a low specificity problem. The comprehensive in vitro proarrhythmia assay (CiPA) project was initiated to correct this problem, which presented a model for classifying the Torsade de pointes (TdP)-induced risk of drugs as biomarkers calculated through an in silico ventricular model. In this study, we propose a TdP-induced risk group classifier of artificial neural network (ANN)-based. The model was trained with 12 drugs and tested with 16 drugs. The ANN model was performed according to nine features, seven features, five features as an individual ANN model input, and the model with the highest performance was selected and compared with the classification performance of the qNet input logistic regression model. When the five features model was used, the results were AUC 0.93 in the high-risk group, AUC 0.73 in the intermediate-risk group, and 0.92 in the low-risk group. The model's performance using qNet was lower than the ANN model in the high-risk group by 17.6% and in the low-risk group by 29.5%. This study was able to express performance in the three risk groups, and it is a model that solved the problem of low specificity, which is the problem of hERG assay.
Keywords
Drug safety assessment; Drug cardiovascular toxicity assessment; Artificial neural network; Machine learning; CiPA;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hwang M, Lim C-H, Leem CH, Shim EB, "In silico models for evaluating proarrhythmic risk of drugs", APL Bioeng., 2020;4(2):021502, doi:10.1063/1.5132618.   DOI
2 Simundic AM, "Measures of Diagnostic Accuracy: Basic Definitions", Ejifcc, 2009:19(4);203-211.
3 Roden DM, "Cellular basis of drug-induced torsades de pointes", Br. J. Pharmacol., 2008;154:1502-1507, doi:10.1038/bjp.2008.238.   DOI
4 Shah RR, "Drugs, QTc interval prolongation and final ICH E14 guideline: An important milestone with challenges ahead", Drug Saf., 2005;28(11):1009-1028, doi:10.2165/00002018- 200528110-00003.   DOI
5 Cavero I, Crumb W, "ICH S7B draft guideline on the nonclinical strategy for testing delayed cardiac repolarisation risk of drugs: A critical analysis", Expert Opin. Drug Saf., 2005;4(3):509-530, doi:10.1517/14740338.4.3.509.   DOI
6 Strauss DG, et al., "Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting", Ther. Innov. Regul. Sci., 2019;53(4):519-525, doi: 10.1177/2168479018795117.   DOI
7 Colatsky T, et al., "The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress", J. Pharmacol. Toxicol. Methods, 2016;81:15-20, doi:10.1016/j.vascn.2016.06.002.   DOI
8 Dutta S, et al., "Optimization of an in silico cardiac cell model for proarrhythmia risk assessment", Front. Physiol., 2017;8:1-15, doi:10.3389/fphys.2017.00616.   DOI
9 Li Z, et al., "Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative", Clin. Pharmacol. Ther., 2019:105(2):466-475, doi: 10.1002/cpt.1184.   DOI
10 Llopis-Lorente J, Gomis-Tena J, Cano J, Romero L, Saiz J, Trenor B, "InSilico Classifiers for the Assessment of Drug Proarrhythmicity", J. Chem. Inf. Model., 2020;60(10):5172-5187, doi:10.1021/acs.jcim.0c00201.   DOI
11 Chang KC, et al., "Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico proarrhythmia risk assessment", Front. Physiol., 2017;8:1-17, doi:10.3389/fphys.2017.00917.   DOI
12 Li Z, et al., "General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy", Clin. Pharmacol. Ther., 2020;107(1):102-111, doi:10.1002/cpt.1647.   DOI
13 Ismail WN, Hassan MM, Alsalamah HA, Fortino G, "CNNbased health model for regular health factors analysis in internetof-medical things environment", IEEE Access, 2020;8:52541-52549, doi:10.1109/ACCESS.2020.2980938.   DOI
14 Lancaster MC, Sobie EA, "Improved Prediction of Drug-Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms", Clin. Pharmacol. Ther., 2016;100(4):371-379, doi:10.1002/cpt.367.   DOI
15 O'Hara T, Virag L, Varro A, Rudy Y, "Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation", PLoS Comput. Biol., 2011;7(5), doi:10.1371/journal.pcbi.1002061.   DOI